• home
  • partners
  • contact
  • Uitgaven
  • partners
  • Vacatures
  • Nieuws
  • Agenda
  • Opleidingen
    • Nucleair Radioloog
    • Klinisch fysicus
    • Medisch nucleair werker
    • Ziekenhuisapotheker
    • Radiochemicus
  • Adverteren
  • Redactie
home > Uitgaven > Jun '25. Value of [18F]FDG PET/CT in the work-up to neoadjuvant systemic therapy in breast cancer

Jun '25. Value of [18F]FDG PET/CT in the work-up to neoadjuvant systemic therapy in breast cancer

Oorspronkelijk artikel

Auteur

L.E.W. Raaijmakers, J. Tol, P.C. Barneveld, M. Bessems

Vakblad

TvNG

Editie

2025-02, juni


 

Download nu

De PDF wordt automatisch gedownload. Afhankelijk van uw browser of device opent deze zich automatisch of staat in de downloads van uw browser

  • Inhoudsopgave

The utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in the initial staging of stage I-IIA breast cancer remains unclear. No firm recommendations on its applicability in these low stages can be drawn from previous research. This single-institution retrospective cohort study was designed to assess the addition of [18F]FDG PET/CT to ultrasonography (US) and magnetic resonance imaging (MRI) in the initial staging of breast cancer patients in work-up to neoadjuvant systemic therapy (NST). Data of 304 patients newly diagnosed with breast cancer between 2018 and 2021 who underwent US, MRI, and [18F]FDG PET/CT for initial staging of breast cancer were evaluated.

Hoofdpartner

Business partners

  • Copyright
  • Algemene voorwaarden
  • Disclaimer
  • Privacy
  • Sitemap
  • Colofon

© Kloosterhof Neer BV